Saturday, May 16, 2026, San Antonio, Texas, 6:00 PM – 7:30 PM Central Time (7:00 PM – 8:30 PM Eastern Time)
Recent Advances in Cancer Care — New Paradigms, Novel Agents and What It Means for the Oncology Nurse: Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer
A Complimentary NCPD Symposium Held During the 51st Annual ONS Congress
Program Schedule — Central Time
5:30 PM – 6:00 PM — Registration and Dinner
6:00 PM – 7:30 PM — Educational Meeting
Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, Texas
Hotel Phone: (210) 223-1000
Meeting Room
Grand Ballroom A-F (Third Floor)
Faculty Jason A Mouabbi, MD
Assistant Professor, Breast Medical Oncology
SAB Chair of the Lobular Breast Cancer Alliance
The University of Texas MD Anderson Cancer Center
Houston, Texas
Additional faculty to be announced.
Moderator
To be announced.
Meeting space has been assigned to provide a symposium supported by AstraZeneca Pharmaceuticals LP, Lilly, and Stemline Therapeutics Inc during the Oncology Nursing Society’s (ONS) 51st Annual Congress, May 13-17, 2026 in San Antonio, TX. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.
Program Schedule — Central Time
5:30 PM – 6:00 PM — Registration and Dinner
6:00 PM – 7:30 PM — Educational Meeting
Topics to Be Discussed
Biology and Current Management of Hormone-Receptor (HR)-Positive Metastatic Breast Cancer (mBC); Clinical Relevance of ESR1 Mutations
Current Clinical Role of Oral Selective Estrogen Receptor Degraders (SERDs) in Therapy for HR-Positive mBC
Tolerability of Currently Approved Oral SERDs
Potential Role of Early Therapeutic Switching After Detection of an Emergent ESR1 Mutation
Adverse Events Associated with Investigational Oral SERDs
Potential Role of Combination Approaches with Oral SERDs for HR-Positive, HER2-Negative Breast Cancer
Tolerability of Combination Approaches and Other Practical Considerations with Oral SERDs
Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer.
Learning Objectives
Upon completion of this activity, participants should be able to
Appreciate the incidence and clinical implications of ESR1 mutations in endocrine-resistant metastatic breast cancer (mBC), and determine optimal strategies to effectively identify patients harboring these abnormalities.
Understand the biological rationale for, mechanism of action of and pharmacologic similarities and differences among available and investigational oral selective estrogen receptor degraders (SERDs).
Interrogate published research documenting the efficacy of oral SERD monotherapy in patients with hormone receptor (HR)-positive, HER2-negative mBC with ESR1 mutations who experience disease progression on standard endocrine therapy in combination with a CDK4/6 inhibitor, in order to optimally understand the role of these agents in patient care.
Review available research findings with serial ESR1 testing using ctDNA as a means to inform early therapeutic switching for patients with HR-positive mBC receiving CDK4/6 inhibitor-based first-line therapy, and consider the clinical applicability of this novel strategy.
Evaluate available clinical trial data with oral SERDs in combination with other systemic therapies, such as CDK4/6 inhibitors or mTOR inhibitors, and consider the potential role of these regimens.
Appreciate side effects associated with available and investigational oral SERDs, and use this information to develop supportive management plans for patients receiving this form of therapy.
Assess ongoing clinical research evaluating novel applications of oral SERDs for HR-positive breast cancer, and counsel patients regarding the potential benefits of trial participation.
Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.
This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.
Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
This program will be submitted for ONCC/ILNA certification.
Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.
Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures will be provided.
FACULTY To be announced.
MODERATOR To be announced.
RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.
Supporters
This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP, Lilly, and Stemline Therapeutics Inc.
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000
Meeting Room
Grand Ballroom A-F (Third Floor)
Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer.
No registration fee is charged for this event. For the in-person symposium in San Antonio, preregistration is required as seating is limited.
NOTICE Registration for this event is independent of registration for the 2026 ONS Congress.
IN-PERSON registration for nurses and healthcare providers
I am a practicing nurse or healthcare provider involved in the care of patients with cancer.
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.
Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.
Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.